ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Toronto, ON, CAN:

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: CC-96673

Phase 1

Celgene
Celgene

Toronto, Ontario, Canada and 12 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

Phase 1, Phase 2

Celgene
Celgene

Toronto, Ontario, Canada and 88 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Toronto, Ontario, Canada and 31 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Toronto, Ontario, Canada and 37 other locations

with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...

Active, not recruiting
B-cell Non-Hodgkin Lymphoma
Drug: Polatuzumab vedotin
Drug: Tocilizumab

Phase 1, Phase 2

Roche
Roche

Hamilton, Ontario, Canada and 28 other locations

participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed folli...

Enrolling
Non-Hodgkin Lymphoma
Drug: Tocilizumab
Drug: Gemcitabine

Phase 3

Roche
Roche

Toronto, Ontario, Canada and 72 other locations

or Pola-R-CHP in participants with untreated diffuse large B-cell lymphoma (DLBCL). Evaluating the safety, preliminary activity, pharmacokin...

Active, not recruiting
B-Cell Lymphoma
Non-Hodgkin Lymphoma
Drug: Obinutuzumab (G)
Drug: Doxorubicin

Phase 1

Roche
Roche

Toronto, Ontario, Canada and 23 other locations

lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).As of October 2022, no furt...

Active, not recruiting
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Drug: Cyclophosphamide
Biological: Brexucabtagene Autoleucel (KTE-X19)

Phase 1, Phase 2

Gilead Sciences
Gilead Sciences

Toronto, Canada and 29 other locations

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK...

Enrolling
Non-Hodgkin's Lymphoma
Drug: Glofitamab
Drug: Obinutuzumab

Phase 1, Phase 2

Roche
Roche

Toronto, Ontario, Canada and 40 other locations

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...

Active, not recruiting
Lymphoma, Non Hodgkin
Lymphocytic Leukemia, Chronic
Drug: BTCT4465A (Mosunetuzumab) IV
Drug: BTCT4465A (Mosunetuzumab) SC

Phase 1, Phase 2

Genentech
Genentech

Toronto, Ontario, Canada and 48 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems